DNAprint Genomics (DNAG)

[dr frudaky]

stockboy

My take is exactly the same as yours. I am somewhat curious by the recent gap up for seemingly no reason at all. The pumpers are still playing the same old cards as reasons for the current spike, but I still do not see anything of substance to warrant or sustain the increase. The dumping and consequent tanking back to .01 and below has probably already begun due to a lack of interest from the awareness that there is really nothing yet to crow about.

The recent bruhaha over Merck's anticipated association with Moffitt and how it will positively impact on DNAG is laughable. There has been no indication that Merck even knows DNAG exists, much less endorsing what it has to offer for a possible revenue deal. Merck is the number 2 pharma in the world and has sufficiently deep pockets to associate with the best personalized medicine company in the world. I believe DNAG has many formidable competitors in that field. Why should Merck cut a deal with DNAG when all the other pharmas have apparently already rejected what it has to offer over the past 7 years? Enquiring minds would like to know the answer to this question!

If you should ever decide to buy back in, God forbid, then I would suggest you wait until it retreats back to .01 or less, or after the second r/s, and hold for the "big news" which all the pumpers are saying will arrive sooner or later. All the current bagholders will just have to grit their teeth and tough it out.

JMHO

dr f